The U.S. digital therapeutics market size was USD 2.45 billion in 2023, calculated at USD 3.02 billion in 2024 and is expected to reach around USD 20.98 billion by 2034, expanding at a CAGR of 21.38% from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on U.S. Digital Therapeutics Market
5.1. COVID-19 Landscape: U.S. Digital Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. U.S. Digital Therapeutics Market, By Application
8.1. U.S. Digital Therapeutics Market, by Application, 2024-2034
8.1.1 Diabetes
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Obesity
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Central Nervous System Diseases
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Cardiovascular Disease (CVD)
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Respiratory Disease
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Smoking Cessation
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Gastrointestinal Disorder (GID)
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2021-2034)
Chapter 9. U.S. Digital Therapeutics Market, By Product
9.1. U.S. Digital Therapeutics Market, by Product, 2024-2034
9.1.1. Software
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Device
9.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 10. U.S. Digital Therapeutics Market, By End Use
10.1. U.S. Digital Therapeutics Market, by End Use, 2024-2034
10.1.1. Patients
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Providers
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Payers
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Employers
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 11. U.S. Digital Therapeutics Market, Regional Estimates and Trend Forecast
11.1. U.S.
11.1.1. Market Revenue and Forecast, by Application (2021-2034)
11.1.2. Market Revenue and Forecast, by Product (2021-2034)
11.1.3. Market Revenue and Forecast, by End Use (2021-2034)
Chapter 12. Company Profiles
12.1. Omada Health Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. 2Morrow Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Teladoc Health, Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pear Therapeutics (U.S), Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Fitbit Health Solutions
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Welldoc, Inc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Click Therapeutics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Noom, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Akili, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Better Therapeutics, Inc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client